Caribou Biosciences Inc (CRBU) - Total Liabilities
Based on the latest financial reports, Caribou Biosciences Inc (CRBU) has total liabilities worth $57.46 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore CRBU shareholders equity momentum to track the company's year-over-year net asset growth rate.
Caribou Biosciences Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Caribou Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. See Caribou Biosciences Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Caribou Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Caribou Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tenaya Therapeutics Inc
NASDAQ:TNYA
|
USA | $22.11 Million |
|
SR Bancorp, Inc. Common stock
NASDAQ:SRBK
|
USA | $959.00 Million |
|
Malaysia Marine and Heavy Engineering Holdings Bhd
KLSE:5186
|
Malaysia | RM1.85 Billion |
|
Thessaloniki Water Supply & Sewerage Co S.A
AT:EYAPS
|
Greece | €55.08 Million |
|
Baiksan
KO:035150
|
Korea | ₩186.04 Billion |
|
Silver X Mining Corp
V:AGX
|
Canada | CA$37.68 Million |
|
Bionime Corp
TW:4737
|
Taiwan | NT$3.95 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Caribou Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CRBU market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Caribou Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Caribou Biosciences Inc (2019–2025)
The table below shows the annual total liabilities of Caribou Biosciences Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $53.19 Million | -11.88% |
| 2024-12-31 | $60.36 Million | -5.40% |
| 2023-12-31 | $63.81 Million | -12.46% |
| 2022-12-31 | $72.89 Million | +33.67% |
| 2021-12-31 | $54.53 Million | -8.33% |
| 2020-12-31 | $59.48 Million | +9.20% |
| 2019-12-31 | $54.47 Million | -- |
About Caribou Biosciences Inc
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapse… Read more